About VWDHigh-Quality VWFFlexibility and DosingCSL Behring CommitmentResources and ToolsHelp Your Patients Learn to Self-infuse Humate-P®Pharmacy ProgramRequest More InformationEducational Program LinksAllAboutBleeding.comDosage CalculatorCustomizable Patient MaterialsVWF Densitometric AnalysisNews and EventsImportant Safety Information for Humate-P®Prescribing Information for Humate-P®Dosage CalculatorVWF Densitometric AnalysisRequest More InfoHumate-P® for Patients

Humate-P® von Willebrand Disease Dosage Calculator

This unique Humate-P® Dosage Calculator makes individual dosing fast, easy, and convenient. The calculator determines the correct Humate-P® loading dose (as measured in VWF:RCo units) needed to achieve the desired increase in circulating VWF, as defined in the product prescribing information. (For guidance on loading dose recommendations, please refer to Table 11 of the PI). All subsequent doses should be based on patient response and measured levels of VWF:RCo and FVIII.

These calculations are to be used only with Humate-P® and are applicable for the treatment of VWD and for the prevention of excessive bleeding during and after surgery in all VWD types.

Humate-P® VWD Dosage Calculator

Instructions: To determine the Humate-P® dose (as measured in VWF:RCo units) needed to achieve the target level of circulating VWF:

1) Enter the patient's body weight (BW) in kilograms (kg) OR pounds (lb)
2) Enter the patient's baseline level (BL) of VWF:RCo (measured as IU VWF:RCo/dL)
3) Enter the patient's target level (TL) of VWF:RCo (measured as IU VWF:RCo/dL)
4) Enter the patient's in vivo recovery (IVR). IVR is measured as rise in IU/dL per IU/kg administered. If unknown, please click on the link next to the IVR field and a value of 2 IU/dL will be used as the default per the dosage instructions in the product prescribing information.

BW   kg  lb 
BL     
TL     
IVR   Click here
to use a default value of 2.0

Based on the following formula, your patient's Humate-P dose is
 VWF:RCo units. 
[TL (IU/dL) - BL (IU/dL)] x BW (kg)   =
IVR (IU/dL)/(IU/kg)
[ __ (IU/dL) - __ (IU/dL)] x __ (kg) = __ VWF:RCo units
 (IU/dL)/(IU/kg)


A full chart of the Humate-P® VWD Dosage Calculator is also available. General Rule: Doses are calculated based on an expected in vivo recovery of 2.0 IU/dL rise in VWF:RCo activity per every IU/kg of VWF:RCo administered.


Printer friendly version


Important Safety Information


Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.

© CSL Behring 2010. The product information presented on this site is intended for US residents only.